Hepatitis B Virus News and Research

RSS

Health providers with hepatitis B are covered by disability law

The U.S. Department of Justice recently declared in a legal settlement that hepatitis B patients are protected by federal disability law.

7 May 2013

First Edition: May 6, 2013

Kaiser Health News staff writer Phil Galewitz, working in collaboration with The Washington Post, reports: "Florida is on course to spend $6 million to reach out to nearly 4 million uninsured people and help them sign up for coverage in the federal health law's online marketplace this fall.

6 May 2013

HCV screening of prison inmate drug users: an interview with Dr. Arthur Kim, Massachusetts General Hospital and Harvard Medical School

Prisoners overall have a very high rate of past or present injection drug use, which is a major risk factor for HCV infection due to repeated exposures to needles.

1 May 2013

BioLineRx starts enrollment in Phase I/II trial of BL-8020 for treatment of HCV

BioLineRx, a biopharmaceutical development company, announced today enrollment of the first patient in a Phase I/II trial for BL-8020, an orally available, interferon-free treatment for the Hepatitis C virus.

29 Apr 2013

Transgene announces pre-clinical data of TG1050 for treatment of chronic hepatitis B infection

Transgene SA, a biopharmaceutical company that develops targeted immunotherapy products to treat major unmet medical needs in cancer and chronic infectious diseases, announced pre-clinical data obtained with its novel immunotherapeutic, TG1050, to treat chronic hepatitis B infection.

29 Apr 2013

Baby boomers need to get tested for hepatitis C

If you were born during 1945-1965, talk to your doctor about getting tested for hepatitis C. Baby boomers are five times more likely than other adults to be infected. In fact, 75 percent of adults with hepatitis C were born during these years.

29 Apr 2013

GS-9620 therapy suppresses hepatitis B virus infection

A novel drug developed by Gilead Sciences and tested in an animal model at the Texas Biomedical Research Institute in San Antonio suppresses hepatitis B virus infection by stimulating the immune system and inducing loss of infected cells.

29 Apr 2013

New hope for patients with chronic HBV infection

Exciting new data presented today at the International Liver Congress- 2013 include rults from early in vitro and in vivo studies targeting covalently closed circular DNA (cccDNA), which may form the basis of a cure for chronic hepatitis B virus (HBV) infection.

25 Apr 2013

Vertex presents data of telaprevir Phase 3b CONCISE study in people with genotype 1 chronic HCV

Vertex Pharmaceuticals Incorporated today announced new data from an interim analysis of the exploratory global Phase 3b CONCISE study evaluating the potential to shorten total treatment with telaprevir combination therapy to 12 weeks in certain people with genotype 1 chronic hepatitis C virus infection who have the IL28B CC genotype.

25 Apr 2013

Janssen submits Marketing Authorization Application to EMA for simeprevir approval

Medivir AB today announces that Janssen-Cilag International NV today has submitted a Marketing Authorization Application to the European Medicines Agency seeking approval for simeprevir (TMC435).

25 Apr 2013

Sofosbuvir is safer than interferon for hepatitis C patients, say scientists

A new drug is offering dramatic cure rates for hepatitis C patients with two subtypes of the infection -- genotype 2 and 3, say a team of scientists led by Weill Cornell Medical College researchers.

25 Apr 2013

Targeted screening for chronic hepatitis C virus infection is cost-effective, say researchers

Researchers at the University of Cincinnati have found that targeted screening for populations with a higher estimated prevalence for hepatitis C may be cost-effective.

25 Apr 2013

Phase IIb Aviator study demonstrates high SVR rates against genotype 1 HCV

Results from "Aviator," AbbVie's phase IIb clinical trial of its investigational direct-acting antivirals for the treatment of hepatitis C virus infection, continue to demonstrate high sustained viral response rates against genotype 1 HCV, across patient types.

24 Apr 2013

Data from MK-5172 Phase II study for treatment of HCV genotype 1 infection to be presented at EASL meeting

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of the latest interim data from a Phase II, multi-center, randomized, dose-ranging clinical trial evaluating the safety and antiviral activity of MK-5172, for the treatment of chronic hepatitis C virus genotype 1 infection.

24 Apr 2013

Home-based health education about diseases most effective, finds study

In the first study of its kind, lay health workers increased screening rates for hepatitis B virus (HBV) and knowledge about the disease among a group of Asian Americans, known as the Hmong, UC Davis researchers have found.

24 Apr 2013

New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, announced today that new Phase 2b data related to ABT-450, Enanta's lead HCV protease inhibitor identified in its ongoing collaboration with AbbVie, as well as new preclinical data on Enanta's proprietary cyclophilin inhibitor, EDP-546, will be presented at the International Liver Congress, which is the 48th Annual Meeting of the European Association for the Study of the Liver taking place in Amsterdam April 24-28, 2013.

23 Apr 2013

Gilead Sciences to present results from four Phase 3 clinical trials at International Liver Congress 2013

Gilead Sciences, Inc. today announced that detailed results from four Phase 3 clinical trials (NEUTRINO, FISSION, POSITRON and FUSION) evaluating sofosbuvir, the company's investigational once-daily nucleotide NS5B inhibitor for the treatment of chronic hepatitis C virus infection, will be presented this week in oral sessions at the 48th Annual Meeting of the European Association for the Study of the Liver in Amsterdam, The Netherlands.

23 Apr 2013

Merck, Bristol-Myers Squibb to evaluate daclatasvir and MK-5172 for treatment of HCV infection

Merck today announced it has entered into a non-exclusive agreement with Bristol-Myers Squibb to conduct a Phase II clinical trial to evaluate the safety and efficacy of a once-daily oral combination regimen consisting of Bristol-Myers Squibb's investigational NS5A replication complex inhibitor daclatasvir and Merck's investigational NS3/4A protease inhibitor MK-5172 for the treatment of chronic hepatitis C virus infection, genotype 1.

23 Apr 2013

DNAzymes, gold nanoparticles and disease detection: an interview with Dr Chan and Kyryl Zagorovsky, University of Toronto

Gold nanoparticles are tiny spherical particles made out of gold atoms with sizes on nanometre scale. This is around 1,000 times smaller than the thickness of human hair.

23 Apr 2013

Tacere Therapeutics submits TT-034 clinical trial application to Recombinant DNA Advisory Committee

RNAi-based therapeutics company Benitec Biopharma Limited today announced that the company's wholly owned US subsidiary, Tacere Therapeutics Inc., has submitted an application to the US National Institutes of Health's Recombinant DNA Advisory Committee.

18 Apr 2013

Hepatitis B Virus News and Research

Health providers with hepatitis B are covered by disability law

First Edition: May 6, 2013

HCV screening of prison inmate drug users: an interview with Dr. Arthur Kim, Massachusetts General Hospital and Harvard Medical School

BioLineRx starts enrollment in Phase I/II trial of BL-8020 for treatment of HCV

Transgene announces pre-clinical data of TG1050 for treatment of chronic hepatitis B infection

Baby boomers need to get tested for hepatitis C

GS-9620 therapy suppresses hepatitis B virus infection

New hope for patients with chronic HBV infection

Vertex presents data of telaprevir Phase 3b CONCISE study in people with genotype 1 chronic HCV

Janssen submits Marketing Authorization Application to EMA for simeprevir approval

Sofosbuvir is safer than interferon for hepatitis C patients, say scientists

Targeted screening for chronic hepatitis C virus infection is cost-effective, say researchers

Phase IIb Aviator study demonstrates high SVR rates against genotype 1 HCV

Data from MK-5172 Phase II study for treatment of HCV genotype 1 infection to be presented at EASL meeting

Home-based health education about diseases most effective, finds study

New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress

Gilead Sciences to present results from four Phase 3 clinical trials at International Liver Congress 2013

Merck, Bristol-Myers Squibb to evaluate daclatasvir and MK-5172 for treatment of HCV infection

DNAzymes, gold nanoparticles and disease detection: an interview with Dr Chan and Kyryl Zagorovsky, University of Toronto

Tacere Therapeutics submits TT-034 clinical trial application to Recombinant DNA Advisory Committee

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News